Myoka Kim Goodin

Partner
RELATED SERVICES

Miki Goodin focuses her practice on complex intellectual property litigation matters with a primary emphasis on disputes involving the Hatch-Waxman provisions of the Patent Act and the Federal Food, Drug and Cosmetic Act.

Miki also represents clients in antitrust litigation actions, provides patent counseling related to the Hatch-Waxman and the Biologics Price Competition and Innovation Acts, and represents both domestic and international clients in a variety of disputes involving their intellectual property.

Miki Goodin focuses her practice on complex intellectual property litigation matters with a primary emphasis on disputes involving the Hatch-Waxman provisions of the Patent Act and the Federal Food, Drug and Cosmetic Act.

Miki also represents clients in antitrust litigation actions, provides patent counseling related to the Hatch-Waxman and the Biologics Price Competition and Innovation Acts, and represents both domestic and international clients in a variety of disputes involving their intellectual property.

Miki has extensive experience in all areas of litigation, from fact discovery (written and depositions), expert discovery (expert reports and depositions), dispositive and preliminary injunction motion practice, through trial and appeals.

Miki is a member of the Firm's Executive Committee and the Chair of the Firm's Litigation Support Committee.

Miki’s representative experience includes:

Hatch-Waxman Litigation:

Ongoing Matters

  • Defending paragraph IV Hatch-Waxman patent infringement action involving:
    • three patents relating to selexipag (Uptravi®)
    • two patents relating to tenofovir alafenamide (Vemlidy®)
    • six patents relating to brexipiprazole (Rexulti®)
    • 12 patents relating to efinaconazole (Jublia®)
    • dapagliflozin (Farxiga®)
    • three patents relating to levomilnacipran (Fetzima®)

Past Matters

  • Defended paragraph IV Hatch-Waxman patent infringement action involving:
    • 10 patents relating to sodium oxybate (Xyrem®) for the treatment of narcolepsy
    • 14 patents relating to icosapent ethyl (Vascepa®) for the reduction of triglycerides in patients with diabetes
    • four patents relating to tavaborole (Kerydin®) for the treatment of nail fungus
    • three patents relating to extended-release oxymorphone hydrochloride (Opana® ER)
    • three patents relating to posaconazole (Noxafil®) for the treatment of fungal infections
    • three patents relating to febuxostat (Uloric®) for the treatment of gout
    • a patent relating to valganciclovir hydrochloride (Valcyte®) for the treatment of viral infections
    • a patent claiming a method of treating attention-deficit/hyperactivity disorder (ADHD) with atomoxetine hydrochloride (Strattera®)
    • a generic antibiotic ophthalmic solution (Zymar®)
    • an antidepressant (Paxil®)
    • a generic extended-release antibiotic product (Biaxin® XL)

Patent Litigation:

  • Represented medical products innovator in patent infringement cases concerning septal occluder devices implanted within the heart via catheter to close holes between the chambers of the heart

Antitrust Litigation:

  • Defended world's largest global electronic payments network in antitrust actions brought by competitor networks
  • Defended electronic payments network in consolidated antitrust class actions brought by merchants relating to fees charged on credit card transactions

Entertainment Litigation:

  • Defended video game manufacturer in action for trademark infringement and other related claims brought under the Lanham Act
  • Represented Japanese film production company in dispute involving producer and director
  • Obtained dismissal of complaint alleging breach of contract, fraud and other causes of action, for one of Japan's largest catalog and mail-order sales companies
RELATED NEWS & EVENTS
CREDENTIALS
Education
  • J.D., University of Southern California Gould School of Law, 2003

    Managing Editor, Southern California Interdisciplinary Law Journal

  • B.A., Molecular and Cell Biology, University of California, Berkeley, 1999
  • B.A., Psychology, University of California, Berkeley, 1999
Bar Admissions
  • California
  • Illinois
Court Admissions
  • U.S. Court of Appeals for the Federal Circuit
  • U.S. District Court for the Central District of California
  • U.S. District Court for the District of Colorado
  • U.S. District Court for the Eastern District of California
  • U.S. District Court for the Northern District of California
  • U.S. District Court for the Northern District of Illinois
  • U.S. District Court for the Southern District of California
Languages
  • Japanese (Native)
Professional Affiliations
    • Member, American Bar Association
    • Member, Locke Lord Executive Committee
Awards & Recognitions
    • Recognized, Notable Women in Law, Crain’s Chicago Business (2020)
    • Recognized, Notable Minorities in Law, Crain's Chicago Business (2019)
Community Leadership
    • Member, Executive Committee, Board of Directors, Domestic Violence Legal Clinic of Chicago